TDOC Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 0.11%. Teladoc Health, Inc.'s return on equity of -15.44% beat Astrana Health, Inc.'s return on equity of 1.85%.

Teladoc Health, Inc. has a consensus price target of $9.21, signalling upside risk potential of 22.3%. On the other hand Astrana Health, Inc. has an analysts' consensus of $40.2500 which suggests that it could grow by 74.85%. Given that Astrana Health, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Astrana Health, Inc. is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.036, which suggesting that the stock is 103.638% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 121.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.52x versus 0.39x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of 9.58%. Teladoc Health, Inc.'s return on equity of -15.44% beat Cryo-Cell International, Inc.'s return on equity of --.

Teladoc Health, Inc. has a consensus price target of $9.21, signalling upside risk potential of 22.3%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 120.78%. Given that Cryo-Cell International, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.036, which suggesting that the stock is 103.638% more volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 16.88% to investors and pays a quarterly dividend of $0.15 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.52x versus 0.98x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Evolent Health, Inc. has a net margin of -7.9% compared to Teladoc Health, Inc.'s net margin of -4.35%. Teladoc Health, Inc.'s return on equity of -15.44% beat Evolent Health, Inc.'s return on equity of -13.6%.

Teladoc Health, Inc. has a consensus price target of $9.21, signalling upside risk potential of 22.3%. On the other hand Evolent Health, Inc. has an analysts' consensus of $10.18 which suggests that it could grow by 160.32%. Given that Evolent Health, Inc. has higher upside potential than Teladoc Health, Inc., analysts believe Evolent Health, Inc. is more attractive than Teladoc Health, Inc..

Teladoc Health, Inc. has a beta of 2.036, which suggesting that the stock is 103.638% more volatile than S&P 500. In comparison Evolent Health, Inc. has a beta of 0.276, suggesting its less volatile than the S&P 500 by 72.421%.

Teladoc Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolent Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health, Inc. pays -- of its earnings as a dividend. Evolent Health, Inc. pays out 32.59% of its earnings as a dividend. Evolent Health, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teladoc Health, Inc. quarterly revenues are $626.4M, which are larger than Evolent Health, Inc. quarterly revenues of $479.5M. Teladoc Health, Inc.'s net income of -$49.5M is lower than Evolent Health, Inc.'s net income of -$20.9M. Notably, Teladoc Health, Inc.'s price-to-earnings ratio is -- while Evolent Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health, Inc. is 0.52x versus 0.22x for Evolent Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.